For the first time, teens with scalp psoriasis have a treatment made just for them.
Taclonex, a topical medication, received Food and Drug Administration (FDA) approval for the treatment of scalp psoriasis in adolescents aged 12 to 17 years old, according to a statement released by LEO Pharma, Taclonex’s manufacturer. The drug is to be used once daily for up to eight weeks, as noted in the statement.
Taclonex, which combines a topical steroid with calcipotriene, a vitamin D analog, had already been approved to treat scalp and body psoriasis in adults. With this new indication, it becomes the first FDA-approved treatment for scalp psoriasis in teenagers on the market, according to the statement.
Because Taclonex is only applied once a day, it could be especially effective in teenagers, who do not always follow more complex treatment directions, said Kelly Cordoro, an associate professor of Dermatology and Pediatrics at the University of California, San Francisco, as quoted in the statement.
Scalp involvement is a common feature of psoriatic disease in children and teenagers.
Driving discovery, creating community
For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.